Cytokinetics (CYTK) to Announce Quarterly Earnings on Thursday

Cytokinetics (NASDAQ:CYTK) is anticipated to announce its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($1.63) per share and revenue of $17.5880 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, meeting analysts’ consensus estimates of ($1.67). The company had revenue of $19.36 million during the quarter, compared to analyst estimates of $8.52 million. During the same period last year, the company earned ($1.36) EPS. The business’s revenue for the quarter was up 1112.5% compared to the same quarter last year. On average, analysts expect Cytokinetics to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Cytokinetics Stock Down 0.9%

NASDAQ:CYTK opened at $76.45 on Tuesday. Cytokinetics has a 12-month low of $32.89 and a 12-month high of $88.31. The stock’s fifty day simple moving average is $78.74 and its 200-day simple moving average is $70.52. The firm has a market capitalization of $9.51 billion, a P/E ratio of -11.18 and a beta of 0.39.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Cytokinetics in a research note on Friday, July 17th. Stifel Nicolaus boosted their target price on Cytokinetics from $98.00 to $108.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Barclays upped their price target on Cytokinetics from $87.00 to $95.00 and gave the company an “overweight” rating in a research note on Monday, April 6th. Morgan Stanley increased their price target on shares of Cytokinetics from $90.00 to $103.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Finally, Wall Street Zen raised shares of Cytokinetics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $99.90.

Insiders Place Their Bets

In other news, CEO Robert I. Blum sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $84.92, for a total transaction of $636,900.00. Following the sale, the chief executive officer owned 377,830 shares of the company’s stock, valued at $32,085,323.60. This trade represents a 1.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director B Lynne Parshall sold 5,000 shares of Cytokinetics stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $74.08, for a total value of $370,400.00. Following the transaction, the director owned 15,784 shares in the company, valued at $1,169,278.72. This trade represents a 24.06% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 115,179 shares of company stock worth $9,126,054. Corporate insiders own 2.60% of the company’s stock.

Institutional Trading of Cytokinetics

Several hedge funds have recently bought and sold shares of CYTK. Kemnay Advisory Services Inc. acquired a new position in shares of Cytokinetics in the fourth quarter valued at approximately $27,000. Kestra Advisory Services LLC acquired a new stake in shares of Cytokinetics during the fourth quarter worth $29,000. Northwestern Mutual Wealth Management Co. lifted its position in Cytokinetics by 46.0% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 543 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 171 shares in the last quarter. Quarry LP bought a new stake in Cytokinetics in the 3rd quarter valued at $30,000. Finally, Advisory Services Network LLC acquired a new position in Cytokinetics in the 3rd quarter worth $32,000.

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.